Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, July 21, 2026, 11:00-11:30 AM CT

Learning Objectives:
  • Explain how transparency and manufacturer partnerships improve quality, consistency, and decision-making confidence in specimen management.
  • Evaluate blood collection tubes beyond cost and commodity assumptions, incorporating clinical impact and risk into decision-making.
  • Assess the potential risk points when using a blood collection device that has not been cleared for a specific purpose.

Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 29, 2026, 1:00-2:00 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.

Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Bio-Rad launches enhanced Liquichek opiate control

December 2025—Bio-Rad Laboratories has launched an enhanced version of its Liquichek opiate control. This version includes updated fentanyl target levels optimized for clinically relevant cutoffs across major chemistry platforms. It contains eight opioid drugs or drug metabolites at concentrations above and below assay cutoffs as recommended by the U.S. Substance Abuse and Mental Health Services Administration, other agencies, and reagent manufacturers.

OGT launches SureSeq Myeloid MRD Plus NGS panel

December 2025—OGT launched the SureSeq Myeloid MRD Plus NGS panel, to detect ultra-low frequency variants in key measurable residual disease–associated biomarkers in acute myeloid leukemia. The panel targets 16 biomarkers associated with AML, including NPM1 and large FLT3 internal tandem duplications, and detects variants at allele frequencies as low as 0.01 percent.

Randox launches a nitazenes array

December 2025—Randox Toxicology has launched its Nitazenes Array, an immunoassay designed to detect a broad spectrum of nitazene analogs from a single sample. The array was developed using Randox’s proprietary biochip array technology and offers a rapid turnaround time. It is available on the company’s Evidence MultiStat platform.

BD enteric bacterial panels get clearance, CE-IVDR certification

December 2025—BD has received FDA 510(k) clearance and CE marking for its Enteric Bacterial Panel and Enteric Bacterial Panel Plus for the BD Cor system. BD EBP offers a range of targets for enteric bacterial pathogens, including Salmonella spp., Campylobacter spp. (C. jejuni, C. coli), Shigella spp./enteroinvasive Escherichia coli, and Shiga toxin–producing E. coli. BD EBP Plus detects enterotoxigenic E. coli and heat-labile and heat-stable enterotoxin genes. The panel also identifies Plesiomonas shigelloides, Vibrio spp. (V. vulnificus, V. parahaemolyticus, V. cholerae), and Yersinia enterocolitica.

Siemens introduces drug testing analyzer

December 2025—Siemens Healthineers has introduced the Atellica DT 250 benchtop analyzer, to help identify substance use, monitor therapeutic and immunosuppressant drugs, and perform serum toxicology testing. It also offers automated specimen validity testing to detect substitution, adulteration, and dilution of urine samples. The analyzer can process 225 test results per hour and provide first results in as few as eight minutes. It features a menu of more than 65 immunoassays for use with urine, serum, and plasma samples and 10 open channels for customizable, user-defined testing.

Primerdesign launches Exsig Mag RapidBead Pro Extraction kit

December 2025—Primerdesign launched its Exsig Mag RapidBead Pro Extraction kit, a next-generation magnetic bead–based kit used to extract high-quality DNA and RNA from diverse sample types. The workflow reduces hands-on time compared to traditional methods and extracts DNA and RNA in less than 20 minutes.

Bruker gets expanded clearance for MALDI Biotyper CA system

December 2025—Bruker announced that its MALDI Biotyper CA system received expanded clearance from the FDA. The clearance includes the MBT Compass HT CA software and MBT Fast Shuttle US IVD as well as an expansion of the FDA-cleared reference library.

Clear Labs collaborates with Labcorp, Pillar Biosciences

December 2025—Clear Labs announced at the Association for Molecular Pathology annual meeting (Boston, Nov. 11–15) its collaboration with Labcorp to automate PGDx kitted oncology NGS assays on the Clear Dx platform. Clear Labs says the collaboration aims to develop streamlined, end-to-end workflows that help laboratories improve efficiency, consistency, and throughput while laying the groundwork for future adoption across a range of genomic applications. This new workflow will expand Clear Labs’ infectious disease applications into oncology testing.

IDT, Beckman Coulter partner to automate NGS workflows

December 2025—Integrated DNA Technologies and Beckman Coulter Life Sciences are forming a strategic partnership to automate IDT’s customizable next-generation-sequencing assay solutions on Beckman Coulter’s newly launched Biomek i3 benchtop liquid handler. Through this partnership, the companies will work to automate IDT’s Archer FusionPlex and VariantPlex targeted sequencing assays and xGen Hybrid Capture workflows on the Biomek i3 system.

HemoSonics gets expanded clearance for Quantra system

December 2025—HemoSonics has received FDA 510(k) clearance for expanded use of its Quantra hemostasis system with QStat cartridges in peripartum obstetric procedures. It is the first FDA-cleared viscoelastic testing platform for obstetric bleeding, according to a company press release. The system uses SEER (sonic estimation of elasticity via resonance) sonorheometry to measure the coagulation properties of a whole blood sample. It provides results in about 15 minutes.

MARKETPLACE

TRENDING